These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 20709651

  • 1. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 2. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.
    World J Gastroenterol; 2014 Apr 21; 20(15):4208-19. PubMed ID: 24764659
    [Abstract] [Full Text] [Related]

  • 3. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
    Lancet Oncol; 2010 Jan 21; 11(1):38-47. PubMed ID: 19942479
    [Abstract] [Full Text] [Related]

  • 4. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY.
    Genet Mol Res; 2011 Oct 03; 10(4):3002-12. PubMed ID: 21968808
    [Abstract] [Full Text] [Related]

  • 5. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 03; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 6. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P.
    Ann Oncol; 2011 Jul 03; 22(7):1535-1546. PubMed ID: 21228335
    [Abstract] [Full Text] [Related]

  • 7. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.
    Int J Clin Oncol; 2013 Aug 03; 18(4):670-7. PubMed ID: 22638623
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J.
    J Clin Oncol; 2013 Jun 01; 31(16):1931-8. PubMed ID: 23569301
    [Abstract] [Full Text] [Related]

  • 9. Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
    Lyseng-Williamson KA.
    Mol Diagn Ther; 2012 Oct 01; 16(5):317-22. PubMed ID: 23055389
    [Abstract] [Full Text] [Related]

  • 10. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
    Chen Y, Cao D, Bi F, Li Q, Qiu M.
    Med Oncol; 2014 May 01; 31(5):935. PubMed ID: 24683007
    [Abstract] [Full Text] [Related]

  • 11. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 12. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.
    World J Gastroenterol; 2014 Apr 21; 20(15):4263-75. PubMed ID: 24764664
    [Abstract] [Full Text] [Related]

  • 13. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
    Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW.
    Cancer Sci; 2013 Apr 21; 104(4):473-80. PubMed ID: 23298313
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct 21; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 15. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.
    World J Gastroenterol; 2010 Jul 07; 16(25):3133-43. PubMed ID: 20593498
    [Abstract] [Full Text] [Related]

  • 16. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
    Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.
    Br J Cancer; 2012 Dec 04; 107(12):1932-7. PubMed ID: 23169296
    [Abstract] [Full Text] [Related]

  • 17. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.
    Invest New Drugs; 2012 Aug 04; 30(4):1607-13. PubMed ID: 21706149
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Aug 04; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 19. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
    Oncology; 2010 Aug 04; 79(5-6):415-22. PubMed ID: 21474966
    [Abstract] [Full Text] [Related]

  • 20. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.
    Ann Oncol; 2012 Jul 04; 23(7):1693-9. PubMed ID: 22219013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.